Certara, Inc. (NASDAQ:CERT) Given Consensus Recommendation of “Hold” by Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have been assigned an average rating of “Hold” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $15.92.

CERT has been the topic of several research reports. Robert W. Baird cut their price objective on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Barclays cut their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th.

Certara Trading Up 1.6 %

CERT opened at $14.23 on Friday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock’s fifty day moving average is $11.53 and its two-hundred day moving average is $11.86. The company has a market capitalization of $2.29 billion, a P/E ratio of -71.15, a PEG ratio of 9.85 and a beta of 1.52. Certara has a 52 week low of $9.41 and a 52 week high of $19.87.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. During the same quarter last year, the firm posted $0.06 earnings per share. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. Analysts forecast that Certara will post 0.28 earnings per share for the current year.

Institutional Trading of Certara

Hedge funds have recently added to or reduced their stakes in the company. Wasatch Advisors LP raised its position in shares of Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock worth $105,577,000 after acquiring an additional 1,651,076 shares during the period. Geneva Capital Management LLC raised its holdings in Certara by 0.7% in the 3rd quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after purchasing an additional 37,392 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Certara by 40.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after purchasing an additional 1,128,006 shares in the last quarter. State Street Corp grew its holdings in Certara by 3.4% in the third quarter. State Street Corp now owns 3,679,699 shares of the company’s stock valued at $43,089,000 after purchasing an additional 122,411 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Certara by 9.7% in the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock valued at $42,643,000 after buying an additional 273,095 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.